FABRAZYME Side Effects

7016109-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Cardiac Failure, Disease Progression, Fabry's Disease, Hepatic Function Abnormal
on Sep 15, 2010 Male patient from JAPAN , 55 years of age, weighting 116.8 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, cardiac failure, disease progression, fabry's disease, hepatic function abnormal. Fabrazyme dosage: 50 Mg, Q2w, Intravenous. During the same period patient was treated with FUROSEMIDE (View Furosemide Review and Furosemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), UBIDECARENONE (UBIDECARENONE) (View Ubidecarenone (ubidecarenone) Review and Ubidecarenone (ubidecarenone) Label ), CARPERITIDE (CARPERITIDE) (View Carperitide (carperitide) Review and Carperitide (carperitide) Label ).

7014637-7 | Arrhythmia, Thrombosis
Patient was taking Fabrazyme (View Usage). Patient had the following side effects: arrhythmia (What is arrhythmia?), thrombosis on Sep 15, 2010 from COLOMBIA Additional patient health information: Male patient , weighting 172.0 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: Unk. During the same period patient was treated with WARFARIN (5 Mg, Qd) (View Warfarin Review and Warfarin Label ), AMIODARONE HCL (25 Mg, Qd) (View Amiodarone Hcl Review and Amiodarone Hcl Label ), BETALOC (25 Mg, Qd) (View Betaloc Review and Betaloc Label ). Patient was hospitalized.

7012206-6 | Angina Pectoris
Adverse event was reported on Sep 15, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 0.7 Mg/kg, Q2w) was diagnosed with fabry's disease and. Location: BRAZIL , weighting 123.5 lb, After Fabrazyme was administered, patient had the following side effects: angina pectoris. Patient was hospitalized.

7000864-1 | Cardiac Failure, Coma, Haemodialysis, Haemorrhagic Stroke, Respiratory Failure
on Sep 10, 2010 Male patient from BRAZIL , weighting 120.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure, coma, haemodialysis, haemorrhagic stroke, respiratory failure. Fabrazyme dosage: 70 Mg, Q2w. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ), EPOGEN (View Epogen Review and Epogen Label ), LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ).


6993030-7 | Haemorrhagic Stroke
on Sep 10, 2010 Male patient from BRAZIL , weighting 120.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: haemorrhagic stroke. Fabrazyme dosage: 70 Mg, Q2w. During the same period patient was treated with RENAGEL (View Renagel Review and Renagel Label ), EPOGEN (View Epogen Review and Epogen Label ), LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ).

6987485-1 | Terminal State
Patient was taking Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: terminal state on Sep 09, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 88.18 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 40 Mg, Q2w.

6965738-0 | Renal Failure Chronic
Adverse event was reported on Aug 31, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 1 Mg/kg, Q2w) was diagnosed with fabry's disease, cardiac failure and. Location: GERMANY , weighting 213.8 lb, Patient experienced the following unwanted or unexpected effects: renal failure chronic. During the same period patient was treated with TORASEMID (20 Mg, Unk) (View Torasemid Review and Torasemid Label ), XIPAMID (40 Mg, Unk) (View Xipamid Review and Xipamid Label ), AMLOPIN (5 Mg, Unk) (View Amlopin Review and Amlopin Label ), ASPIRIN (100 Mg, Unk) (View Aspirin Review and Aspirin Label ).

6957492-3 | Abdominal Pain, Adverse Event, Premature Rupture Of Membranes
on Aug 25, 2010 Female patient from UNITED STATES , weighting 110.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), adverse event, premature rupture of membranes. Fabrazyme dosage: 50 Mg, Q2w. During the same period patient was treated with PRILOSEC (View Prilosec Review and Prilosec Label ), PANCREASE MT (View Pancrease Mt Review and Pancrease Mt Label ), LIDOCAINE HCL VISCOUS (View Lidocaine Hcl Viscous Review and Lidocaine Hcl Viscous Label ), HI COSAMINE (View Hi-cosamine Review and Hi-cosamine Label ), VICODIN (View Vicodin Review and Vicodin Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), TYLENOL 500 (650 Mg, Prn) (View Tylenol-500 Review and Tylenol-500 Label ), TYLENOL 500 (650 Mg, Q2w) (View Tylenol-500 Review and Tylenol-500 Label ). Patient was hospitalized.

6936707-1 | Arterial Stenosis, Cardiac Output Decreased, Respiratory Failure
on Aug 10, 2010 Male patient from GERMANY , weighting 146.6 lb, was diagnosed with fabry's disease, hypertension, cardiac disorder, haemodilution, vitamin d, vitamin supplementation and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: arterial stenosis, cardiac output decreased, respiratory failure. Fabrazyme dosage: Unk. During the same period patient was treated with BISOPROLOL (Unk) (View Bisoprolol Review and Bisoprolol Label ), PLAVIX (Unk) (View Plavix Review and Plavix Label ), SORTIS (20 Mg, Qd) (View Sortis Review and Sortis Label ), EINSALPHA (1 Mcg, Qd) (View Einsalpha Review and Einsalpha Label ), CINACALCET HYDROCHLORIDE (60 Mg, Qd) (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), CPS (Unk) (View Cps Review and Cps Label ), VITARENAL (Unk) (View Vitarenal Review and Vitarenal Label ).

6928172-5 | Paraesthesia, Renal Failure
Patient was taking Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: paraesthesia, renal failure on Aug 04, 2010 from TURKEY Additional patient health information: Male patient , weighting 167.6 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: .

6925196-9 | Acute Myocardial Infarction, Renal Impairment
Adverse event was reported on Aug 09, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 105 Mg, Q2w) was diagnosed with fabry's disease, cardiac disorder, nephropathy and. Location: NORWAY , weighting 220.5 lb, Patient had the following side effects: acute myocardial infarction, renal impairment. During the same period patient was treated with REPLAGAL (Unk) (View Replagal Review and Replagal Label ), METOPROLOL (50 Mg, Qd) (View Metoprolol Review and Metoprolol Label ), LOSARTAN POTASSIUM (100 Mg, Qd) (View Losartan Potassium Review and Losartan Potassium Label ), ENALAPRIL (5 Mg, Qd) (View Enalapril Review and Enalapril Label ), ATORVASTATIN (80 Mg, Qd) (View Atorvastatin Review and Atorvastatin Label ), SALICYLIC ACID (75 Mg, Qd) (View Salicylic Acid Review and Salicylic Acid Label ).

6921720-0 | Chest Discomfort, Chills, Hyperaesthesia, Paraesthesia, Pyrexia, Respiratory Disorder
on Aug 09, 2010 Male patient from COLOMBIA , weighting 185.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: chest discomfort, chills, hyperaesthesia, paraesthesia, pyrexia, respiratory disorder. Fabrazyme dosage: 1.5 Mg/kg, Q2w.

6920091-3 | Renal Failure
on Aug 05, 2010 Male patient from UNITED STATES , weighting 131.0 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure. Fabrazyme dosage: 65 Mg, Q2w. Patient was hospitalized.

6910838-4 | Renal Failure Chronic
Patient was taking Fabrazyme (View Usage). Patient had the following side effects: renal failure chronic on Aug 03, 2010 from GERMANY Additional patient health information: Male patient , weighting 213.8 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 1 Mg/kg, Q2w.

6909306-5 | Peritonitis, Sepsis
Adverse event was reported on Jul 30, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 1 Mg/kg, Q2w) was diagnosed with fabry's disease and. Location: ARGENTINA , 33 years of age, After Fabrazyme was administered, patient had the following side effects: peritonitis, sepsis (What is sepsis?).

6905792-5 | Cardiac Disorder
on Jul 26, 2010 Male patient from UNITED STATES , 45 years of age, weighting 88.18 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac disorder. Fabrazyme dosage: 0.3 Mg/kg, Q2w.

6905581-1 | Abdominal Pain Upper, Diarrhoea, Limb Injury, Pain In Extremity, Protein Total Increased, Sensory Loss, Sluggishness
on Jul 27, 2010 Male patient from UNITED STATES , weighting 150.1 lb, was diagnosed with fabry's disease, hypothyroidism and was treated with Fabrazyme (View Usage). Patient had the following side effects: abdominal pain upper, diarrhoea, limb injury, pain in extremity, protein total increased, sensory loss, sluggishness. Fabrazyme dosage: 70 Mg, Q4w. During the same period patient was treated with THYROID HORMONES (View Thyroid Hormones Review and Thyroid Hormones Label ). Patient was hospitalized.

6887267-5 | Renal Failure Chronic, Renal Transplant
Patient was taking Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: renal failure chronic, renal transplant on Jul 16, 2010 from SWEDEN Additional patient health information: Male patient , 36 years of age, weighting 189.6 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 70 Mg, Q2w, Intravenous. During the same period patient was treated with TEGRETOL (View Tegretol Review and Tegretol Label ), PERSANTIN (View Persantin Review and Persantin Label ), ETALPHA (ALFACALCIDOL) (View Etalpha (alfacalcidol) Review and Etalpha (alfacalcidol) Label ), RENAGEL (View Renagel Review and Renagel Label ), NATRIUMBIKARBONAT (SODIUM BICARBONATE) (View Natriumbikarbonat (sodium Bicarbonate) Review and Natriumbikarbonat (sodium Bicarbonate) Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ALBYL (ACETYLSALICYLIC ACID) (View Albyl (acetylsalicylic Acid) Review and Albyl (acetylsalicylic Acid) Label ). Patient was hospitalized.

6880562-5 | Brain Mass, Myocardial Infarction
Adverse event was reported on Jul 15, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 90 Mg, Q4w) was diagnosed with fabry's disease and. Location: UNITED STATES , weighting 195.3 lb, Patient experienced the following unwanted or unexpected effects: brain mass, myocardial infarction. During the same period patient was treated with BENADRYL (View Benadryl Review and Benadryl Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6874664-7 | Accident, Contusion, Dizziness, Fall, Head Injury, Neck Injury, Product Contamination Physical, Skin Laceration
on Jul 09, 2010 Male patient from UNITED STATES , 47 years of age, weighting 198.4 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: accident, contusion, dizziness (What is dizziness?), fall (What is fall?), head injury, neck injury, product contamination physical, skin laceration. Fabrazyme dosage: 40 Mg, Q3w, Intravenous, 90 Mg, Q2w, Intravenous. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6862783-0 | Deafness Bilateral
on Jul 13, 2010 Male patient from FRANCE , weighting 152.1 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: deafness bilateral. Fabrazyme dosage: 0.5 Mg/kg, Q3w.

6847754-2 | Brain Stem Haemorrhage, Pleural Effusion, Renal Failure
Patient was taking Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: brain stem haemorrhage, pleural effusion, renal failure on Jul 08, 2010 from JAPAN Additional patient health information: Female patient , weighting 88.18 lb, was diagnosed with fabry's disease, renal failure, hypertension, prophylaxis and. Fabrazyme dosage: 1 Mg/kg, Q2w. During the same period patient was treated with LOSARTAN POTASSIUM (50 Mg, Unk) (View Losartan Potassium Review and Losartan Potassium Label ), DIPYRIDAMOLE (150 Mg, Unk) (View Dipyridamole Review and Dipyridamole Label ), ENALAPRIL MALEATE (5 Mg, Unk) (View Enalapril Maleate Review and Enalapril Maleate Label ), RABEPRAZOLE SODIUM (10 Mg, Qd) (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ). Patient was hospitalized.

6843034-X | Body Temperature Increased, Eczema, Eosinophil Percentage Increased, Feeling Hot
Adverse event was reported on Jun 24, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 0.5 Mg/kg, Once, Intravenous, 70 Mg, Once, Intravenous, 0.2 Mg/kg, Once, Intravenous) was diagnosed with fabry's disease and. Location: JAPAN , 17 years of age, weighting 121.3 lb, Patient had the following side effects: body temperature increased, eczema (What is eczema?), eosinophil percentage increased, feeling hot. During the same period patient was treated with REPLAGAL (AGALSIDASE ALFA) (View Replagal (agalsidase Alfa) Review and Replagal (agalsidase Alfa) Label ).

6838319-7 | Bronchitis, Cardiac Failure Chronic, Condition Aggravated
on Jun 23, 2010 Female patient from JAPAN , 67 years of age, weighting 105.8 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: bronchitis (What is bronchitis?), cardiac failure chronic, condition aggravated. Fabrazyme dosage: 50 Mg, Q2w, Intravenous, 50 Mg, Q2w, Intravenous. During the same period patient was treated with ALACEPRIL (ALACEPRIL) (View Alacepril (alacepril) Review and Alacepril (alacepril) Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), URSODIOL (View Ursodiol Review and Ursodiol Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

6835319-8 | Accident, Dizziness, Fall, Head Injury, Neck Injury, Product Quality Issue
on Jun 23, 2010 Male patient from UNITED STATES , 47 years of age, weighting 198.4 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: accident, dizziness (What is dizziness?), fall (What is fall?), head injury, neck injury, product quality issue. Fabrazyme dosage: 40 Mg, Q3w, Intravenous. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), PREDNISONE (PREDISONE) (View Prednisone (predisone) Review and Prednisone (predisone) Label ).

6832264-9 | Chest Discomfort, Chills, Hyperaesthesia, Paraesthesia, Pyrexia, Respiratory Disorder
Patient was taking Fabrazyme (View Usage). Patient had the following side effects: chest discomfort, chills, hyperaesthesia, paraesthesia, pyrexia, respiratory disorder on Jun 29, 2010 from COLOMBIA Additional patient health information: Male patient , 37 years of age, weighting 185.2 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 1.5 Mg/kg, Q2w.

6832092-4 | Perforated Ulcer
Adverse event was reported on Jul 02, 2010 by a Female patient taking Fabrazyme (View Usage) (Dosage: Unk) was diagnosed with fabry's disease and. Location: UNITED STATES , weighting 132.3 lb, After Fabrazyme was administered, patient had the following side effects: perforated ulcer. Patient was hospitalized.

6822320-3 | Cardiac Failure, Device Lead Damage, Hypotension, Transient Ischaemic Attack
on Jun 25, 2010 Male patient from UNITED STATES , weighting 132.3 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure, device lead damage, hypotension, transient ischaemic attack. Fabrazyme dosage: 60 Mg, Unk. During the same period patient was treated with REPLAGAL (0.2 Mg/kg, Once) (View Replagal Review and Replagal Label ). Patient was hospitalized.

6818997-9 | Azotaemia, Cardiac Arrest, Cardiac Failure Chronic, Condition Aggravated, Cyanosis, Hypotension, Renal Failure Chronic, Respiratory Arrest, Urine Output Decreased
on Jun 23, 2010 Female patient from JAPAN , 69 years of age, weighting 110.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: azotaemia, cardiac arrest (What is cardiac arrest?), cardiac failure chronic, condition aggravated, cyanosis, hypotension, renal failure chronic, respiratory arrest, urine output decreased. Fabrazyme dosage: 50 Mg, Q2w, Intravenous. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), WARFARIN POTASSIUM (WARFARIN POTASSIUM) (View Warfarin Potassium (warfarin Potassium) Review and Warfarin Potassium (warfarin Potassium) Label ), CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), ALACEPRIL (ALACEPRIL) (View Alacepril (alacepril) Review and Alacepril (alacepril) Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ). Patient was hospitalized.

6795507-6 | Pleural Effusion
Patient was taking Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: pleural effusion on Jun 22, 2010 from JAPAN Additional patient health information: Female patient , weighting 88.18 lb, was diagnosed with fabry's disease, renal failure, hypertension, gastric ulcer and. Fabrazyme dosage: 1 Mg/kg, Q2w. During the same period patient was treated with LOSARTAN POTASSIUM (50 Mg, Unk) (View Losartan Potassium Review and Losartan Potassium Label ), DIPYRIDAMOLE (150 Mg, Unk) (View Dipyridamole Review and Dipyridamole Label ), ENALAPRIL MALEATE (5 Mg, Unk) (View Enalapril Maleate Review and Enalapril Maleate Label ), RABEPRAZOLE SODIUM (10 Mg, Unk) (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ), FUROSEMIDE (20 Mg, Unk) (View Furosemide Review and Furosemide Label ), ALFACALCIDOL (0.25 Mg, Unk) (View Alfacalcidol Review and Alfacalcidol Label ). Patient was hospitalized.

6786007-8 | Chest Pain, Coronary Artery Occlusion, Myocardial Infarction, Renal Failure, Vasoconstriction
Adverse event was reported on Jun 21, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 35 Mg, Unk) was diagnosed with fabry's disease, chest pain (What is chest pain?) and. Location: UNITED STATES , weighting 154.3 lb, Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), coronary artery occlusion, myocardial infarction, renal failure, vasoconstriction. During the same period patient was treated with NITROGLYCERIN (Unk) (View Nitroglycerin Review and Nitroglycerin Label ), ZOCOR (Unk) (View Zocor Review and Zocor Label ), BENADRYL (50 Mg, Unk) (View Benadryl Review and Benadryl Label ), ACETAMINOPHEN (1 G, Unk) (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6785768-1 | Transient Ischaemic Attack
on Jun 16, 2010 Female patient from UNITED STATES , weighting 176.4 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: transient ischaemic attack. Fabrazyme dosage: 40 Mg, Q2w. During the same period patient was treated with REPLAGAL (Unk) (View Replagal Review and Replagal Label ). Patient was hospitalized.

6785759-0 | Myocardial Infarction, Renal Impairment
on Jun 16, 2010 Male patient from FRANCE , weighting 92.59 lb, was diagnosed with fabry's disease, cardiac failure, hypertension, thrombosis prophylaxis, hyperlipidaemia, epilepsy (What is epilepsy?) and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: myocardial infarction, renal impairment. Fabrazyme dosage: 35 Mg, Q2w. During the same period patient was treated with CARDENSIEL (Unk) (View Cardensiel Review and Cardensiel Label ), TRIATEC (Unk) (View Triatec Review and Triatec Label ), PLAVIX (Unk) (View Plavix Review and Plavix Label ), TAHOR (Unk) (View Tahor Review and Tahor Label ), DIHYDANTOIN (Unk) (View Dihydantoin Review and Dihydantoin Label ), TEGRETOL (Unk) (View Tegretol Review and Tegretol Label ).

6781909-0 | Pleural Effusion, Renal Failure
Patient was taking Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: pleural effusion, renal failure on Jun 10, 2010 from JAPAN Additional patient health information: Female patient , weighting 88.18 lb, was diagnosed with fabry's disease, renal failure, hypertension, gastric ulcer and. Fabrazyme dosage: 1 Mg/kg, Q2w. During the same period patient was treated with LOSARTAN POTASSIUM (50 Mg, Unk) (View Losartan Potassium Review and Losartan Potassium Label ), DIPYRIDAMOLE (150 Mg, Unk) (View Dipyridamole Review and Dipyridamole Label ), ENALAPRIL MALEATE (5 Mg, Unk) (View Enalapril Maleate Review and Enalapril Maleate Label ), RABEPRAZOLE SODIUM (10 Mg, Unk) (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ), FUROSEMIDE (20 Mg, Unk) (View Furosemide Review and Furosemide Label ), ALFACALCIDOL (0.25 Mg, Unk) (View Alfacalcidol Review and Alfacalcidol Label ). Patient was hospitalized.

6771475-8 | Hypokalaemia, Muscular Weakness, Pain In Extremity, Spinal Disorder
Adverse event was reported on Jun 04, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 70 Mg, Q2w) was diagnosed with fabry's disease and. Location: GERMANY , weighting 151.2 lb, Patient had the following side effects: hypokalaemia, muscular weakness, pain in extremity, spinal disorder. During the same period patient was treated with DIGITOXIN (0.07 Mg, Qd) (View Digitoxin Review and Digitoxin Label ), KARVEA (75 Mg, Qd) (View Karvea Review and Karvea Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), TORSEMIDE (50 Mg, Bid) (View Torsemide Review and Torsemide Label ), FALITHROM (View Falithrom Review and Falithrom Label ). Patient was hospitalized.

6770248-X | Bacteraemia, Bacterial Infection, Chills, Device Related Infection, Infusion Related Reaction, Nausea, Pyrexia, Renal Failure Acute, Staphylococcal Infection
on May 28, 2010 Female patient from UNITED STATES , 39 years of age, weighting 196.9 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: bacteraemia, bacterial infection (What is bacterial infection?), chills, device related infection, infusion related reaction, nausea (What is nausea?), pyrexia, renal failure acute, staphylococcal infection (What is staphylococcal infection?). Fabrazyme dosage: 90 Mg,q3w,intravenous. During the same period patient was treated with IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), BENADRYL (View Benadryl Review and Benadryl Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), PHENERGAN HCL (View Phenergan Hcl Review and Phenergan Hcl Label ), SODIUM CHLORIDE (View Sodium Chloride Review and Sodium Chloride Label ), LAMICTAL (View Lamictal Review and Lamictal Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), NORVASC (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

6768909-1 | Bacteraemia, Blood Culture Positive, Burning Sensation, Catheter Culture Positive, Chills, Device Related Infection, Heart Rate Increased, Pain, Pain In Extremity
on May 28, 2010 Male patient from UNITED STATES , 14 years of age, weighting 102.1 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: bacteraemia, blood culture positive, burning sensation, catheter culture positive, chills, device related infection, heart rate increased, pain (What is pain?), pain in extremity. Fabrazyme dosage: 35 Mg, Intravenous; 45 Mg, Q2w, Intravenous. During the same period patient was treated with LYRICA (View Lyrica Review and Lyrica Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), MOTRIN (View Motrin Review and Motrin Label ). Patient was hospitalized.

6768908-X | Accident, Dizziness, Fall, Head Injury, Neck Injury
Patient was taking Fabrazyme (View Usage). Patient had the following side effects: accident, dizziness (What is dizziness?), fall (What is fall?), head injury, neck injury on May 24, 2010 from UNITED STATES Additional patient health information: Male patient , 47 years of age, weighting 198.4 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 40 Mg, Q3w, Intravenous; 90 Mg, Q2w, Intravenous. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ).

6762298-4 | Renal Failure
Adverse event was reported on May 28, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 65 Mg, Q2w) was diagnosed with fabry's disease and. Location: UNITED STATES , weighting 131.0 lb, After Fabrazyme was administered, patient had the following side effects: renal failure. Patient was hospitalized.

6760726-1 | Chest Discomfort, Chills, Hyperaesthesia, Paraesthesia, Pyrexia, Respiratory Disorder
on May 26, 2010 Male patient from COLOMBIA , 37 years of age, weighting 185.2 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: chest discomfort, chills, hyperaesthesia, paraesthesia, pyrexia, respiratory disorder. Fabrazyme dosage: 1.5 Mg/kg, Q2w.

6760478-5 | Cardiac Arrest, Renal Disorder
on Jun 02, 2010 Male patient from FRANCE , 55 years of age, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), renal disorder. Fabrazyme dosage: 1 Mg/kg, Unk. Patient was hospitalized.

6739815-3 | Myocardial Infarction, Renal Impairment
Patient was taking Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: myocardial infarction, renal impairment on May 17, 2010 from FRANCE Additional patient health information: Male patient , weighting 92.59 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: Unk.

6739692-0 | Cardiac Disorder, Pulmonary Embolism, Renal Failure Chronic
Adverse event was reported on May 13, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 35 Mg, Q4w) was diagnosed with fabry's disease and. Location: UNITED STATES , weighting 145.3 lb, Patient experienced the following unwanted or unexpected effects: cardiac disorder, pulmonary embolism (What is pulmonary embolism?), renal failure chronic.

6739514-8 | Cardio-respiratory Arrest, Hypertensive Crisis, Multi-organ Failure
on May 13, 2010 Male patient from BRAZIL , weighting 104.7 lb, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient had the following side effects: cardio-respiratory arrest, hypertensive crisis, multi-organ failure. Fabrazyme dosage: 0.7 Mg/kg, Q2w. During the same period patient was treated with ANTIHYPERTENSIVES (NOS) (View Antihypertensives (nos) Review and Antihypertensives (nos) Label ). Patient was hospitalized.

6733566-7 | Chest Pain, Coronary Artery Occlusion, Myocardial Infarction, Renal Failure, Vasoconstriction
on May 11, 2010 Male patient from UNITED STATES , weighting 154.3 lb, was diagnosed with fabry's disease, chest pain (What is chest pain?) and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: chest pain (What is chest pain?), coronary artery occlusion, myocardial infarction, renal failure, vasoconstriction. Fabrazyme dosage: 35 Mg, Unk. During the same period patient was treated with NITROGLYCERIN (Unk) (View Nitroglycerin Review and Nitroglycerin Label ), ZOCOR (Unk) (View Zocor Review and Zocor Label ), BENADRYL (50 Mg, Unk) (View Benadryl Review and Benadryl Label ), ACETAMINOPHEN (1 G, Unk) (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6733108-6 | Accident, Chills, Dizziness, Fall, Feeling Cold, Feeling Hot, Flushing, Head Injury, Infusion Related Reaction
Patient was taking Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: accident, chills, dizziness (What is dizziness?), fall (What is fall?), feeling cold, feeling hot, flushing, head injury, infusion related reaction on May 04, 2010 from UNITED STATES Additional patient health information: Male patient , 47 years of age, weighting 198.4 lb, was diagnosed with fabry's disease and. Fabrazyme dosage: 40 Mg, Q3w, Intravenous, 90 Mg, Q2w, Iv.

6723491-X | Cardiac Disorder, Pulmonary Embolism, Renal Failure Chronic
Adverse event was reported on May 05, 2010 by a Male patient taking Fabrazyme (View Usage) (Dosage: 35 Mg, Q4w) was diagnosed with fabry's disease and. Location: UNITED STATES , weighting 145.3 lb, Patient had the following side effects: cardiac disorder, pulmonary embolism (What is pulmonary embolism?), renal failure chronic.

6718496-9 | Cytomegalovirus Infection, Incorrect Dose Administered, Infection In An Immunocompromised Host, Renal Failure, Renal Transplant, White Blood Cell Count Decreased
on Apr 23, 2010 Male patient from UNITED STATES , weighting 110.2 lb, was diagnosed with fabry's disease, infection (What is infection?) and was treated with Fabrazyme (View Usage). After Fabrazyme was administered, patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), incorrect dose administered, infection in an immunocompromised host, renal failure, renal transplant, white blood cell count decreased. Fabrazyme dosage: 45 Mg, Q2w, Intravenous. During the same period patient was treated with VALCYTE (View Valcyte Review and Valcyte Label ). Patient was hospitalized.

6717341-5 | Cardiac Arrest, Renal Disorder
on Apr 28, 2010 Male patient from FRANCE , 55 years of age, was diagnosed with fabry's disease and was treated with Fabrazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), renal disorder. Fabrazyme dosage: 1 Mg/kg, Unk. Patient was hospitalized.

6715703-3 | Chest Pain, Coronary Artery Occlusion, Vasoconstriction
Patient was taking Fabrazyme (View Usage). Patient had the following side effects: chest pain (What is chest pain?), coronary artery occlusion, vasoconstriction on Apr 27, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 154.3 lb, was diagnosed with fabry's disease, chest pain (What is chest pain?) and. Fabrazyme dosage: 35 Mg, Q2w. During the same period patient was treated with NITROGLYCERIN (Unk) (View Nitroglycerin Review and Nitroglycerin Label ), ZOCOR (Unk) (View Zocor Review and Zocor Label ), BENADRYL (View Benadryl Review and Benadryl Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.